FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896920574> ?p ?o ?g. }

• W2896920574 endingPage "e0204823" @default.
• W2896920574 startingPage "e0204823" @default.
• W2896920574 abstract "Background Finasteride, a 5-alpha reductase inhibitor may have effects on biomarkers such as prostate-specific antigen (PSA) that could be leveraged to improve screening. Objective To determine the predictive characteristics of biomarkers for prostate cancer for cancer on biopsy following 3 months of finasteride use compared with placebo. Design, setting and participants 383 men from multiple clinical sites with intermediate prostate cancer risk, without history of prostate cancer, were randomly allocated in a double-blinded manner, 4:1, to receive either finasteride or placebo for 90 days at which time a prostate biopsy was performed. Outcome measurements and statistical analysis The primary outcomes were associations of biomarkers with prostate cancer that were tested using multiple logistic regression and area under the receiver operating curves (AUC). Biomarkers for PCA risk (PCA3, TMPRSS2:ERG (T2:ERG) gene product, and PSA) were measured at baseline and at biopsy in a blinded fashion to assess the predictive performance of baseline levels, 90-day levels, and measures of change relative to standard predictors. Results and limitations A total of 292 (233 finasteride; 59 placebo) randomized patients underwent biopsy and were analyzed. On finasteride, baseline and 90-day measures of PCA3 and T2:ERG had similar moderate discrimination capacity with AUCs 62 to 65% (p-values < 0.001 and 0.001, respectively), but their rates of change had no discrimination ability (AUC 51%, (95% CI 43 to 60% p = 0.72) and 48% (95% CI 44 to 60%, p = 0.62), respectively).) Relative to baseline, the 90-day PCA3 and PSA decreased in the finasteride group by 25% and 50%, respectively (both p<0.001). T2:ERG had a smaller, non-significant change post finasteride treatment (p = 0.08). Conclusions Short-term finasteride therapy did not improve performance of the most commonly-employed prostate cancer biomarkers. Threshold values for new biomarkers of prostate cancer should be interpreted with caution in patients receiving finasteride until formal validation of test performance in these patients is conducted. Patient summary Three months of finasteride treatment did not increase the accuracy for predicting the outcome on prostate biopsy but did have a significant effect on biomarker values. Adjustments to thresholds for biopsy for men on finasteride are proposed. Trial registration ClinicalTrials.gov, NCT01296672." @default.
• W2896920574 created "2018-10-26" @default.
• W2896920574 creator A5009108510 @default.
• W2896920574 creator A5015887484 @default.
• W2896920574 creator A5024582072 @default.
• W2896920574 creator A5035733667 @default.
• W2896920574 creator A5037307507 @default.
• W2896920574 creator A5056530679 @default.
• W2896920574 creator A5061399098 @default.
• W2896920574 creator A5068893673 @default.
• W2896920574 date "2018-10-09" @default.
• W2896920574 modified "2023-10-14" @default.
• W2896920574 title "The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial" @default.
• W2896920574 cites W1908218485 @default.
• W2896920574 cites W1980309257 @default.
• W2896920574 cites W2017264713 @default.
• W2896920574 cites W2024097324 @default.
• W2896920574 cites W2038565121 @default.
• W2896920574 cites W2050465965 @default.
• W2896920574 cites W2061891797 @default.
• W2896920574 cites W2078573596 @default.
• W2896920574 cites W2089798048 @default.
• W2896920574 cites W2095761465 @default.
• W2896920574 cites W2096544053 @default.
• W2896920574 cites W2098905361 @default.
• W2896920574 cites W2111866018 @default.
• W2896920574 cites W2128733308 @default.
• W2896920574 cites W2130474576 @default.
• W2896920574 cites W2131034333 @default.
• W2896920574 cites W2134793522 @default.
• W2896920574 cites W2140687262 @default.
• W2896920574 cites W2160699421 @default.
• W2896920574 cites W2169385858 @default.
• W2896920574 cites W2468726924 @default.
• W2896920574 doi "https://doi.org/10.1371/journal.pone.0204823" @default.
• W2896920574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6177134" @default.
• W2896920574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30300367" @default.
• W2896920574 hasPublicationYear "2018" @default.
• W2896920574 type Work @default.
• W2896920574 sameAs 2896920574 @default.
• W2896920574 citedByCount "6" @default.
• W2896920574 countsByYear W28969205742021 @default.
• W2896920574 countsByYear W28969205742022 @default.
• W2896920574 countsByYear W28969205742023 @default.
• W2896920574 crossrefType "journal-article" @default.
• W2896920574 hasAuthorship W2896920574A5009108510 @default.
• W2896920574 hasAuthorship W2896920574A5015887484 @default.
• W2896920574 hasAuthorship W2896920574A5024582072 @default.
• W2896920574 hasAuthorship W2896920574A5035733667 @default.
• W2896920574 hasAuthorship W2896920574A5037307507 @default.
• W2896920574 hasAuthorship W2896920574A5056530679 @default.
• W2896920574 hasAuthorship W2896920574A5061399098 @default.
• W2896920574 hasAuthorship W2896920574A5068893673 @default.
• W2896920574 hasBestOaLocation W28969205741 @default.
• W2896920574 hasConcept C103796816 @default.
• W2896920574 hasConcept C118487528 @default.
• W2896920574 hasConcept C121608353 @default.
• W2896920574 hasConcept C126322002 @default.
• W2896920574 hasConcept C126894567 @default.
• W2896920574 hasConcept C142724271 @default.
• W2896920574 hasConcept C143998085 @default.
• W2896920574 hasConcept C204787440 @default.
• W2896920574 hasConcept C27081682 @default.
• W2896920574 hasConcept C2775874879 @default.
• W2896920574 hasConcept C2775934546 @default.
• W2896920574 hasConcept C2776235491 @default.
• W2896920574 hasConcept C2780192828 @default.
• W2896920574 hasConcept C2780827179 @default.
• W2896920574 hasConcept C2781217009 @default.
• W2896920574 hasConcept C2781406297 @default.
• W2896920574 hasConcept C71924100 @default.
• W2896920574 hasConcept C87874733 @default.
• W2896920574 hasConceptScore W2896920574C103796816 @default.
• W2896920574 hasConceptScore W2896920574C118487528 @default.
• W2896920574 hasConceptScore W2896920574C121608353 @default.
• W2896920574 hasConceptScore W2896920574C126322002 @default.
• W2896920574 hasConceptScore W2896920574C126894567 @default.
• W2896920574 hasConceptScore W2896920574C142724271 @default.
• W2896920574 hasConceptScore W2896920574C143998085 @default.
• W2896920574 hasConceptScore W2896920574C204787440 @default.
• W2896920574 hasConceptScore W2896920574C27081682 @default.
• W2896920574 hasConceptScore W2896920574C2775874879 @default.
• W2896920574 hasConceptScore W2896920574C2775934546 @default.
• W2896920574 hasConceptScore W2896920574C2776235491 @default.
• W2896920574 hasConceptScore W2896920574C2780192828 @default.
• W2896920574 hasConceptScore W2896920574C2780827179 @default.
• W2896920574 hasConceptScore W2896920574C2781217009 @default.
• W2896920574 hasConceptScore W2896920574C2781406297 @default.
• W2896920574 hasConceptScore W2896920574C71924100 @default.
• W2896920574 hasConceptScore W2896920574C87874733 @default.
• W2896920574 hasFunder F4320332161 @default.
• W2896920574 hasIssue "10" @default.
• W2896920574 hasLocation W28969205741 @default.
• W2896920574 hasLocation W28969205742 @default.
• W2896920574 hasLocation W28969205743 @default.
• W2896920574 hasLocation W28969205744 @default.
• W2896920574 hasOpenAccess W2896920574 @default.
• W2896920574 hasPrimaryLocation W28969205741 @default.

• next